Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized peptide-lipid drug conjugates comprising a neuromedin U NMU2 receptor agonist peptide. They are reported to be useful for the treatment of obesity.
This news pertains to the field of Endocrine/metabolic research and was covered in BioWorld Science under the Patents category. The information was dated Feb. 2, 2026.
